Literature DB >> 11703840

Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.

B Gryseels1, A Mbaye, S J De Vlas, F F Stelma, F Guissé, L Van Lieshout, D Faye, M Diop, A Ly, L A Tchuem-Tchuenté, D Engels, K Polman.   

Abstract

This paper summarizes and concludes in-depth field investigations on suspected resistance of Schistosoma mansoni to praziquantel in northern Senegal. Praziquantel at 40 mg/kg usually cures 70-90% of S. mansoni infections. In an initial trial in an epidemic S. mansoni focus in northern Senegal, only 18% of the cases became parasitologically negative 12 weeks after treatment, although the reduction in mean egg counts was within normal ranges (86%). Among other hypotheses to explain the observed low cure rate in this focus, the possibility of drug resistance or tolerance had to be considered. Subsequent field trials with a shorter follow-up period (6-8 weeks) yielded cure rates of 31-36%. Increasing the dose to 2 x 30 mg/kg did not significantly improve cure rates, whereas treatment with oxamniquine at 20 mg/kg resulted in a normal cure rate of 79%. The efficacy of praziquantel in this focus could be related to age and pre-treatment intensity but not to other host factors, including immune profiles and water contact patterns. Treatment with praziquantel of individuals from the area residing temporarily in an urban region with no transmission, and re-treatment after 3 weeks of non-cured individuals within the area resulted in normal cure rates (78-88%). The application of an epidemiological model taking into account the relation between egg counts and actual worm numbers indicated that the low cure rates in this Senegalese focus could be explained by assuming a 90% worm reduction after treatment with praziquantel; in average endemic situations, such a drug efficacy would result in normal cure rates. Laboratory studies by others on the presence or absence of praziquantel resistance in Senegalese schistosome strains have so far been inconclusive. We conclude that there is no convincing evidence for praziquantel-resistant S. mansoni in Senegal, and that the low cure rates can be attributed to high initial worm loads and intense transmission in this area.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703840     DOI: 10.1046/j.1365-3156.2001.00811.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  60 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.

Authors:  Nuno Vale; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Fátima Gärtner; José M Correia da Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Expression and characterization of lactate dehydrogenase from Schistosoma japonicum.

Authors:  Gang Lu; Xuchu Hu; Zhaiyu Peng; Hongyan Xie; Yanwen Li; Zhongdao Wu; Xinbing Yu
Journal:  Parasitol Res       Date:  2006-05-11       Impact factor: 2.289

4.  Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice.

Authors:  Omaima Mohammed Abou-Shady; Soheir Sayed Mohammed; Samar Sayed Attia; Hebat-Allah Salah Yusuf; Dina Omar Helmy
Journal:  J Parasit Dis       Date:  2014-06-01

Review 5.  Susceptibility or resistance of praziquantel in human schistosomiasis: a review.

Authors:  Wei Wang; Li Wang; You-Sheng Liang
Journal:  Parasitol Res       Date:  2012-10-07       Impact factor: 2.289

6.  Phage displaying peptides mimic schistosoma antigenic epitopes selected by rat natural antibodies and protective immunity induced by their immunization in mice.

Authors:  Min Wang; Xin-Yuan Yi; Xian-Ping Li; Dong-Ming Zhou; McReynolds Larry; Xian-Fang Zeng
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

7.  Effect of a novel benzimidazole derivative in experimental Schistosoma mansoni infection.

Authors:  Serry A El Bialy; Amira Taman; Samar N El-Beshbishi; Basem Mansour; Mohamed El-Malky; Waleed A Bayoumi; Hassan M Essa
Journal:  Parasitol Res       Date:  2013-10-06       Impact factor: 2.289

Review 8.  The role of evolutionary biology in research and control of liver flukes in Southeast Asia.

Authors:  Pierre Echaubard; Banchob Sripa; Frank F Mallory; Bruce A Wilcox
Journal:  Infect Genet Evol       Date:  2016-05-16       Impact factor: 3.342

9.  Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Authors:  Sandra D Melman; Michelle L Steinauer; Charles Cunningham; Laura S Kubatko; Ibrahim N Mwangi; Nirvana Barker Wynn; Martin W Mutuku; Diana M S Karanja; Daniel G Colley; Carla L Black; William Evan Secor; Gerald M Mkoji; Eric S Loker
Journal:  PLoS Negl Trop Dis       Date:  2009-08-18

10.  Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children.

Authors:  Mahamadou S Sissoko; Abdoulaye Dabo; Hamidou Traoré; Mouctar Diallo; Boubacar Traoré; Drissa Konaté; Boubacar Niaré; Moussa Diakité; Bourama Kamaté; Abdrahamane Traoré; Aboudramane Bathily; Amadou Tapily; Ousmane B Touré; Sarah Cauwenbergh; Herwig F Jansen; Ogobara K Doumbo
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.